Optimising Cognitive Screening In General Practice
Funder
National Health and Medical Research Council
Funding Amount
$300,550.00
Summary
Within the next 5 - 10 years it is likely that sophisticated combination pharmacotherapy for Alzheimer's disease will become available. Once intervention agents are available that affect the underlying disease process, it will be critical to accurately identify those patients who are in the earliest stages of cognitive decline. That is, failure to detect cognitive decline at an early stage will reduce the effectiveness of the intervention and be costly to the individual and society. At the same ....Within the next 5 - 10 years it is likely that sophisticated combination pharmacotherapy for Alzheimer's disease will become available. Once intervention agents are available that affect the underlying disease process, it will be critical to accurately identify those patients who are in the earliest stages of cognitive decline. That is, failure to detect cognitive decline at an early stage will reduce the effectiveness of the intervention and be costly to the individual and society. At the same time, the probability of falsely identifying an individual as having Alzheimer's disease needs to be reduced in order to avoid unnecessary testing, anxiety and distress, and expense. A sophisticated and highly flexible testing system to detect the earliest stages of memory impairment will be developed. The test will be administered over the web in a general practitioner's surgery enabling the collection of normative data on the population of greatest interest (elderly patients seeing their doctor). Voice recognition technology will be used in order to insure a user friendly environment. Stringent procedures to protect privacy will be employed. The test will be inexpensive and easy to take and will allow valid retesting so that it can be used as part of the routine health screening for the elderly. This will be a far more sensitive and specific indicator of the cognitive decline found in most neurodegenerative disorders such as Alzheimer's disease, and will enable general practitioners to be more confident in assessing their older patients. It will also reduce costly referrals by more accurately identifying those patients at risk. It is expected that the test will find acceptance amongst patients and their doctors and become a routine part of normal health screening for the elderly.Read moreRead less
The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very si ....The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very simple. A drug which makes cells less sensitive to X-rays (these drugs are called radioprotectors) is simply applied topically to the normal tissues at risk. For this purpose, we have developed a new radioprotecting drug called methylproamine which is 100-fold more potent than previously-developed radioprotectors. Unfortunately, methylproamine is not suitable for our purpose because at higher concentrations it is toxic to some cells. This hurdle must be overcome in order to make the project attractive to potential commercial sponsors. Our aim is to modify methylproamine by removing the molecular features that cause the cytotoxicity. We have established that this is feasible, by synthesising and evaluating a small family of methylproamine analogues. Some less toxic family members have already been identified. With this knowledge, we now propose to use special computer programmes to design a much larger family of methylproamine analogues, and to synthesise and test each one in order to identify the most promising candidate for our purpose. Once the efficacy window hurdle is passed, the subsequent milestones to commercialisation and clinical implementation can be addressed, with appropriate sponsorship. An Australian company has already expressed strong interest and is evaluating the opportunity.Read moreRead less